MTOR and nonpapillary renal cell carcinoma: Despite some progress, therapy targeting of VEGF and mTOR signaling has an presents few clinic effect in patients with PRCC, while the efficacy of VEGFR-targeted therapies and mTOR inhibitors has been demonstrated in clinical trials in patients with ccRCC (Tannir et al., 2016).